Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-arm, Multicenter, Phase II Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification

NCT05214339 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05214339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05214339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-arm, Multicenter, Phase II Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Unknown status
Start date
March 16, 2022
Completion date
June 1, 2023
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma by bclc stage, unresectable hepatocellular carcinoma